3rd International Conference on Chemo and BioInformatics, Kragujevac, September 25-26. 2025. (pp. 489-492)
АУТОР(И) / AUTHOR(S): Milica Međedović Stefanović, Ana Rilak Simović, Nenad Janković, Emilija Milović, Biljana Petrović
Download Full Pdf 
DOI: 10.46793/ICCBIKG25.489MS
САЖЕТАК / ABSTRACT:
Ruthenium complexes occupied an important place in a group of transition metal complexes that were synthesized to replace platinum-based complexes and provide better selectivity and lower toxicity. This study involves creating three new ruthenium (η6-p-cymene) complexes with the formula [(η6-p-cym)Ru(O–O)Cl] using O,O-diketo ester ligands called ethyl 2- hydroxy-4-aryl-4-oxobut-2-enoate (1–3). The interactions with the blood transport protein HSA were studied to see how well the complexes could reach their target. The mentioned interactions were monitored by fluorescence spectroscopy with HSA alone and with the addition of the site markers Eosin Y (a marker for site I of subdomain IIA) and Ibuprofen (a marker for site II of subdomain IIIA). The site markers were used to precisely localize the binding site in the transported blood protein. The influence of bidentate ligands on binding efficacy was assessed by examining the calculated binding constants. Based on in vitro HSA experiments, complex 1 exhibited the highest HSA activity, suggesting that the presence of an alkene chain contributes to increased activity.
КЉУЧНЕ РЕЧИ / KEYWORDS:
Ruthenium(II), HSA, site markers, interactions
ПРОЈЕКАТ / ACKNOWLEDGEMENT:
The authors are grateful for financial support to the Institute for Information Technologies Kragujevac (Grant No J01-34/2023) and to the Ministry of Science, Technological Development, and Innovation of the Republic of Serbia (Grant agreement no. 451-03-136/2025-03/200378)
ЛИТЕРАТУРА / REFERENCES:
- C. Zhang, C. Xu, X. Gao, Q. Yao, Platinum-based drugs for cancer therapy and anti-tumor strategies, Theranostics, 12 (2022) 2115–2132.
- A. F.A. Peacock, P.J. Sadler, Medicinal organometallic chemistry: designing metal Arene complexes as anticancer agents, Chemistry: An Asian Journal, 3 (2008) 1890–1899.
- C. A. Vock, A.K. Renfrew, R. Scopelliti, L. Juillerat-Jeanneret, P.J. Dyson, Influence of the Diketonato Ligand on the Cytotoxicities of [Ru( η + 6-p-cymene)(R 2 acac)(PTA)] Complexes (PTA = 1,3,5-triaza-7-phosphaadamantane), European Journal of Inorganic Chemistry, 2008 (2008) 1661–1671.
- C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurenczy, T. J. Geldbach, Sava, P.J. Dyson, In vitro and in vivo evaluation of ruthenium(II)- arene PTA complexes, Journal of Medicinal Chemistry, 48 (2005) 4161–4171.